# Structure Therapeutics Inc. (GPCR) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $20.35, market value $1.5 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Structure Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 1.1×**. The shares trade at 1.1× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -15.5%** (5-yr avg -2.1%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -9.3%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): -2.6%**. Earnings per share fell 2.6%.

## Financial health
- **Current ratio: 24.81** (quick 24.81). Current assets cover the next year's liabilities 24.81 times.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Structure Therapeutics Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): -38.6%** (YTD -70.6%, 3-mo -57.7%). The shares are down 38.6% over twelve months including dividends.
- **From 52-week high: -78.6%** (0.2% above the low). Trading 79% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 23**. An RSI of 23 is oversold; bounces are common, but oversold can stay oversold in a real decline.
- **Beta (1 yr): 1.02** (volatility 119%). Beta of 1.02 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=GPCR · Page: https://foliofundamentals.com/stocks/gpcr

Not investment advice.